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The QJM has recently published reviews of novel therapies in
chronic airways disease.1 There is a potentially novel role for
glucagon-like peptide 1 (GLP-1) agonists in obesity-related,
metabolic asthma, though clinical trial data are lacking.2 On the
basis of work with other inflammatory states, we hypothesised
that clinically-indicated use of GLP-1 agonists for glycaemic
control in type 2 diabetes mellitus (T2DM) would be safe in
those with concomitant asthma, potentially leading to im-
proved asthma control and fewer asthma exacerbations.3 In a
pilot observational cohort study, we prospectively identified
nine patients with pulmonologist-diagnosed asthma (never-
smokers) and concomitant T2DM who were about to be initiated
on clinically-indicated liraglutide for T2DM in the course of rou-
tine clinical care, and assessed them for asthma-related indices
at baseline and 52 weeks after initiating liraglutide. All received
routine asthma care. Baseline characteristics of the study co-
hort are as shown (Table 1). Seven of the nine subjects who
commenced therapy with liraglutide remained on therapy for
the 52 week duration of the study (i.e. ‘adherent’), while two
subjects (‘non-adherent’) came off liraglutide before 8 weeks
due to non-asthma-related side effects (diarrhoea, epigastric
discomfort, night sweats, hypoglycaemia and headaches) but
were included in the analysis. At week 52 of liraglutide therapy,
the mean weight loss was 4.9 kg (5.6% of baseline mean weight)
with median weight loss value of 2.9 kg. HbA1c at week 52 fell to
51.9 mmol/mol (mean). Over the 52 weeks of therapy, the great-
est falls in weight and HbA1c were in those who remained
adherent to liraglutide, accompanied by clinically significant
improvements in asthma control including asthma symptoms
and exacerbations (Figure 1). No subject adherent to liraglutide
had a clinically significant deterioration of asthma. One non-
fatal severe exacerbation occurred, which happened several
weeks subsequent to early discontinuation of liraglutide in the
(non-adherent) subject, who had 2.9 kg of weight loss in the
study. This could reflect withdrawal of liraglutide or poor-
adherence to other asthma controller medicines. The changes
in asthma-related outcomes could not be linked to changes in
dosage of other asthma controller medicines. We conclude that
use of liraglutide to treat concomitant T2DM was safe and po-
tentially helpful for co-morbid overweight/obese asthma. This
is consistent with animal/in vitro/ex vivo studies that have as-
sessed the effects of GLP-1 analogues in asthma, but could also
be coincidental or represent an observer effect in a small uncon-
trolled cohort study.4,5 Given the growing clinical exposure of
patients to GLP-1 agonists, the proof of concept data herein pro-
vides a further imperative for large randomised controlled stud-
ies assessing the role of GLP-1 analogues in overweight/obese
asthma patients with and without T2DM.
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Table 1. Baseline demographic and other clinical variables among
T2DM participants with concomitant asthma completing 52 weeks
of follow up
Parameter Value
N 9
Gender (male/female) 4/5
Age (yr) 61.96 2.3
Smoking status (never/former/current) 9/0/0
Family history of asthma (yes/no) 3/6
Asthma onset (youth onset/late onset 5/4
Weight (kg) 886 5
BMIa (kg/m2) 32.36 2.5
Asthma acute exacerbation rate (annual) 2.66 0.62
Asthma controllers, n on any ICSb 8
GINAc treatment step (step 1/2/3/4/5) 1/1/3/4/0
ACQd score 1.036 0.1
AQLQe overall score 5.596 0.2
AQLQ symptom score 5.806 0.2
AQLQ activity score 5.576 0.3
AQLQ emotional score 5.566 0.4
AQLQ environmental stimuli score 5.066 0.3
Severe asthma (n)f 4
FVCg (post-bronchodilator) L 3.56 0.3
FEV1h (post-bronchodilator)L 2.346 0.2
% FEV1/FVC (post-bronchodilator) 67.86 3
HbA1ci (<48 mmol/mol) 57.06 1.7
aBMI, body mass index.
bICS, inhaled corticosteroids.
cGINA, Global Initiative for Asthma.
dACQ, Asthma Control Questionnaire.
eAQLQ, Asthma Quality of Life Questionnaire.
fSevere asthma defined as per International ERS/ATS guidelines on definition,
evaluation and treatment of severe asthma.
gFVC, forced vital capacity.
hFEV1, forced expiratory volume of air in 1 s.
iHbA1c, glycated haemoglobin (A1c).
Figure 1. Asthma-related outcomes in subjects whose weight loss was greater or
less than the median weight loss of 2.9 kg. A. Mean ACQ score pre- and post-
52 weeks of liraglutide therapy, parsed on the ordinate by those with greater-
than-median weight loss of 2.9 kg and those with less-than-median weight loss.
B. Similar to A, but showing the number of asthma exacerbations in the year
prior to (week 0, black bars) and the year following initiation of liraglutide (week
52, grey bars), and parsed into mild and moderate exacerbations for each weight
grouping (the only severe exacerbation observed in the study occurred in a
non-adherent subject post-discontinuation of liraglutide). In panels A and B, an
asterisk (*) denotes a clinically significant change, reflecting minimal clinically
important difference (MCID) where known. ACQ, Juniper Asthma Control
Questionnaire.
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